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Endocytosis mediates the cellular uptake of micronutrients and turnover of plasma 19	
membrane proteins. Clathrin-mediated endocytosis (CME) is the major uptake pathway in 20	
resting cells1, but several Clathrin-independent endocytic (CIE) routes exist in parallel2,3. One 21	
such pathway, fast Endophilin-mediated endocytosis (FEME), is not constitutive but triggered 22	
upon activation of certain receptors including β1 adrenergic receptor (β1-AR)4. FEME activates 23	
promptly following stimulation as Endophilin is pre-enriched by the Pi(3,4)P2-binding protein 24	
Lamellipodin (Lpd)4,5. However, in the absence of stimulation, Endophilin foci abort and 25	
disassemble after a few seconds. Looking for additional proteins involved in FEME, we found 26	
that 20 out of 65 BAR domain-containing proteins tested colocalized with Endophilin spots.  27	
Among them, FBP17 and CIP4 prime the membrane of resting cells for FEME by recruiting the 28	
5’-lipid phosphatase SHIP2 and Lpd to mediate local production of Pi(3,4)P2 and Endophilin 29	
pre-enrichment. Membrane-bound GTP-loaded Cdc42 recruits FBP17 and CIP4, before being 30	
locally deactivated by RICH1 and SH3BP1 GAPs. This generates the transient assembly and 31	
disassembly of Endophilin spots, which last 5-10 seconds. This mechanism periodically 32	
primes patches of membrane for prompt responses upon FEME activation.   33	
 34	
FEME requires the stimulation of cargo receptors by their ligands to trigger the prompt budding of 35	
endocytic carriers from the plasma membrane3. FEME carriers are defined as cytoplasmic, Clathrin-negative, 36	
Endophilin-positive assemblies (EPAs). The pre-recruitment of Endophilin A (sub-family comprising A1, A2 37	
and A3 in human) into discrete foci on the plasma membrane before receptor activation may enable FEME to be 38	
very responsive to cargo activation6. If Endophilin is not pre-enriched, FEME does not take place and cargo 39	
receptors either accumulate at the cell surface or enter cells through other alternative pathways3,4. Endophilin 40	
binds to the plasma membrane through its Bin1/Amphiphysin/Rvs161/167 (BAR) domain but is concentrated at 41	
endocytic sites by Lamellipodin which itself binds to locally produced Pi(3,4)P2REF4,5. In absence of stimulation, 42	
the foci abort and disassemble after few seconds and new ones form nearby (Supplementary Video 1). This is 43	
reminiscent to Clathrin-coated pits that frequently abort if they are not stabilized by cargoes and fail to reach a 44	
critical size7. However, the spatially localized clustering of Endophilin (prominent at the leading edge) and 45	
abortion ahead of FEME activation and endocytic carrier building suggest instead an active mechanism. 46	
 In order to identify proteins regulating FEME, we performed pulldown assays using recombinant SH3 47	
domains of Endophilin A1 to 3 (hereafter EndoA1 to 3) and rat brain lysates and identified the binding partners 48	
by mass spectrometry (Supplementary Fig. 1a and Table 1). Whilst known interactors such as Dynamin and 49	
Synaptojanin were detected, several BAR domain containing proteins were detected. This prompted us to test the 50	
binding of the EndoA2 SH3 domain to all BAR proteins containing putative Endophilin-binding proline-rich 51	
motifs8 in their primary sequences. We found that Endophilin bound to RICH1 (also called Nadrin-1), SH3BP1, 52	
ACAP1, ASAP1, and srGAP1, 2 and 3 but not to the other BAR proteins tested (Supplementary Fig. 1b). The 53	
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lack of binding of EndoA2 SH3 domain to Pacsin 1-3 (also called Syndapin 1-3) in HEK293 cells extracts 54	
suggests potential differences in tissue-specific complexes or post-translational modifications (in particular 55	
phosphorylation) between brain and non-neuronal tissues. Together with the previously known binding of 56	
Endophilin to Oligophrenin-1REF9 (hereafter OPHN1) and Bin2REF10, this suggested that several BAR domain 57	
proteins in addition to Endophilin, could be involved in FEME. A role for several of them during the 58	
invagination of EPAs in the absence of a dense protein coat would be coherent with their capacity to sense and 59	
induce membrane curvature and functions in local actin nucleation11-13. 60	
To test this, we cloned 65 BAR proteins known in human (Supplementary Fig. 1c and 1a) and tested 61	
for their colocalization with endogenous Endophilin foci at the leading edge of resting cells, an area where 62	
Endophilin is strongly recruited, but very few clathrin-coated structures are present4. We used BSC1 cells as all 63	
but 3 of the BAR proteins tested (FAM92B, Pacsin1 and PSTPIP1) are expressed in kidney, their tissue of origin 64	
(Supplementary Fig. 2). Each EGFP-tagged construct was titrated down to achieve low expression and 65	
colocalization with endogenous Endophilin staining was measured on confocal microscope images using line 66	
scans (Supplementary Fig. 3 and 4a-c). To minimize artifactual colocalization, we used the membrane-bound 67	
probe CAAX-EGFP as negative control and applied the stringent criterion that both Endophilin and the BAR 68	
protein candidate must be enriched on discrete puncta over their surrounding signals (Supplementary Fig. 3b). 69	
Therefore any Endophilin foci being located within diffuse BAR protein signals that extend beyond a punctum 70	
(such as Arfaptin 1-2, Pick1, RICH2 or GRAF1) were scored negative. Overall, out of the 65 BAR proteins 71	
tested, 20 colocalized with high significance (p<0.01) with Endophilin (Fig. 1a and Supplementary Fig. 3 and 72	
4a-c). Interestingly, only Amphiphysin, Bin1, Bin2, ICA1-L, RICH1, SH3BP1, OPHN1, ASAP1 and PSTPIP1 73	
were detected on more than 50% of the foci. FBP17, CIP4, SNX9, Nostrin, Pacsin1 to 3, and srGAP1 to 3 were 74	
detected on a subset of puncta, suggesting that they either marked a subgroup of Endophilin spots or a different 75	
timing of recruitment. It is important to note that amongst the BAR proteins identified, only Bin1, RICH1, 76	
SH3BP1, ASAP1, FBP17, CIP4, Pacsin2 and srGAP1 and 2 are expressed in most human tissues 77	
(Supplementary Fig. 2a), suggesting a potential tissue-specific role for the other candidates. Conscious of the 78	
possible artifacts induced by expressing EGFP-tagged transgenes, albeit at lowest possible levels, we validated 79	
the colocalization of the candidates for which commercial antibodies were available. We confirmed that 80	
endogenous Bin1, CIP4, RICH1, ASAP1, SNX9, Pacsin2 and srGAP1 colocalized to various extent with 81	
endogenous Endophilin in BSC1 cells and also in human normal diploid retinal pigmented epithelial (hTERT-82	
RPE1) cells (Fig. 1b-c).  83	
Activation of several receptors including β1 adrenergic receptor (β1-AR) triggers FEME4. Stimulation 84	
of cells with β1-AR agonists induces the prompt (<10 sec) formation of FEME carriers, that contained 85	
endogenous β1-AR but not CME cargoes such as transferrin (Fig. 1c-d and Supplementary Fig. 4d). Following 86	
longer incubation times (>30 min), endogenous β1-AR internalized and accumulated into LAMP-1-positive 87	
endosomes in an Endophilin-dependent but AP2-independent manner (Fig. 1c and Supplementary Fig. 4f), 88	
confirming that FEME and not CME was the main endocytic pathway for β1-ARREFS4,14. Even though Bin1 and 89	
Amphiphysin colocalized on most Endophilin spots at the leading edge, their double knock down (DKD) did not 90	
affect β1-AR uptake, suggesting that they were either redundant or not involved in the internalization of this 91	
particular cargo. By contrast, despite their colocalization on less than 50% of the Endophilin foci, FBP17 and 92	
CIP4 were required for the uptake of β1-AR (Fig. 1c-dand Supplementary Fig. 4e). FBP17, CIP4 and TOCA-1 93	
form a sub-group of the F-BAR protein family, having similar domain organization consisting in a F-BAR, HR1 94	
(also called REM) and SH3 domains. We found that, as for several other BAR protein sub-families, FBP17, 95	
CIP4 and TOCA-1 can heterodimerize through their BAR domains (Supplementary Fig. 1c-d), suggesting 96	
redundancy or cooperation in their functions.  97	
FBP17 and CIP4 are involved in CME and recruited at late stages of clathrin-coated pit formation15-17, 98	
as well as into oscillating waves on the plasma membrane18,19. Their role in β1-AR uptake and their clustering 99	
into spots on the leading edge of resting cells (Fig. 1b and 2a) suggested an additional role in FEME.  100	
FBP17 and CIP4 did not bind to β1-AR and were not recruited on budded FEME carriers (Fig. 1e and 101	
2b). The inhibition of β1-AR uptake in F+C DKD cells was consistent with the strong reduction (89.3 ± 4.7%) 102	
of FEME carrier formation upon receptor activation (Fig. 2c). By contrast, overexpression of FBP17 or CIP4, 103	
but not that of TOCA-1, increased the formation of EPAs by over 2-fold upon stimulation (Fig. 2d). These were 104	
productive FEME carriers, as measured by receptor interaction with Endophilin (proximity ligation assay, PLA) 105	
	 3 
and β1-AR uptake (Fig. 2e-f). The stimulatory effect was PI3K- and Endophilin-dependent (Fig. 2e-f and Video 106	
3), consistent with the FEME mechanism. The recruitment of Endophilin was strongly reduced (86.3 ± 5.2%) in 107	
F+C DKD cells and significantly increased in FBP17 or CIP4-overexpressing cells (Fig. 2c-d). Consistent with 108	
their nucleating activity, they were recruited 8 ± 4 sec before the flashes of Endophilin (Fig. 2g-h and Videos 4 109	
and 5). This explains their low degree of colocalization in fixed samples (Fig. 1a-b). Upon receptor activation, 110	
the frequency of spot nucleation increased by over 2 fold but the duration of CIP4 or Endophilin and their order 111	
of arrival did not change (Fig. 2h). By contrast, β1-AR was only recruited to Endophilin spots upon activation. 112	
CIP4 overexpression boosted the frequency of spot nucleation and prolonged the spot duration (Fig. 2h), which 113	
explains the increase in FEME observed in this condition (Fig. 2d-f). Thus, we concluded that FBP17 and CIP4 114	
were upstream of Endophilin, and were required to recruit it in transient puncta and to prime the membrane of 115	
resting cells for FEME.  116	
FBP17 and CIP4 were recently found to bind to SHIP1 and 2 in mast cells and to precede them by ~5 117	
sec on the membrane19. In fibroblasts, SHIP2 is known to be recruited to the leading edge and to hydrolyse 118	
Pi(3,4,5)P3 into Pi(3,4)P2 within seconds20. We confirmed that FBP17 and CIP4 bound to the ubiquitously 119	
expressed SHIP2 and found that they colocalized with it at the leading edge in BSC1 cells (Fig. 3a-b). CIP4 was 120	
still recruited to the leading edge in absence of SHIP1 and 2 but not the other way around. Double depletion of 121	
SHIP1 and 2 was performed because of the low expression of SHIP1 in kidney (Supplementary Fig. 2b) that 122	
could compensate SHIP2 depletion. FBP17 and CIP4 also bound to Lpd and recruited it to the leading edge (Fig. 123	
3a and b). Systematic depletion and overexpression of the various players revealed that FBP17 and CIP4 recruit 124	
SHIP2 and Lpd, which then enrich Endophilin at the leading edge of resting cells (Fig. 3d-f). We found that 125	
SHIP2 was functionally upstream of Lpd, suggesting that local Pi(3,4)P2 production was required to stabilize 126	
Lpd which is recruited by FBP17 and CIP4. Inhibiting SHIP2 not only strongly reduced the frequency and 127	
duration of the priming spots in resting cells, it also blocked the recruitment of β1-AR by Endophilin into FEME 128	
carriers (Fig. 3h-j and Video 6). 129	
FBP17, CIP4 and TOCA-1 are Cdc42 effectors that bind to the active (GTP-loaded) form through their 130	
REM motifs21,22. Inhibiting Cdc42 using ML141 or Secramine or by overexpressing a dominant-negative form 131	
was sufficient to strongly reduce endogenous CIP4 recruitment to the leading edges, even in cells depleted for 132	
Endophilin (Fig. 4a-e). Inhibiting Cdc42 also hindered the recruitment of SHIP2, Lpd and Endophilin to the 133	
leading edge, placing active Cdc42 upstream of them all. CIP4 recruitment to the leading edge was narrowed 134	
down to its REM domain (Fig. 4f-h) as only truncated constructs containing this motif were recruited to the 135	
leading edge in FBP17+CIP4+TOCA-1 TKD cells (to avoid recruitment of the transgenes by heterodimerization 136	
through the BAR domain of endogenous proteins). Inhibiting Cdc42 prevented the recruitment of the isolated 137	
REM domain. Thus, active Cdc42 recruits FBP17 and CIP4 to prime cells for FEME.  138	
Intriguingly, acute inhibition (2 min) of Cdc42 induced the paradoxical hyperactivation of FEME in the 139	
first few minutes4, but longer incubation (>10 min) inhibits it (Supplementary Fig. 5a). This suggested that 140	
cycles of activation and inhibition of Cdc42 were required for the transient and periodic recruitment of FBP17 141	
and CIP4 and in foci. Amongst the BAR proteins binding to Endophilin and colocalizing with it at the leading 142	
edges are RICH1, SH3BP1 and OPHN1 (Fig. 1a-b and Supplementary Fig. 1-3), which are Cdc42 GAPsREFS23-143	
25. Overexpression of RICH1, SH3BP1 or OPHN1 but not that of their GAP mutated forms inhibited Endophilin 144	
recruitment in resting cells, while the depletion of RICH1 and SH3BP1 (R+S DKD) enhanced the phenotype 145	
(Fig. 5a-c and Supplementary Fig. 5b). However, CIP4 and Lpd were still recruited to the leading edge of 146	
resting R+S DKD cells. RICH1 required FBP17 and CIP4 but not Lpd or Endophilin for its recruitment to the 147	
leading edge (Fig. 5b and Supplementary Fig. 5c-d). This is consistent with the binding of RICH1, SH3BP1 148	
and OPHN1 to FBP17 (Supplementary Fig. 5e) and CIP4REF24. Akin to CIP4 overexpression, the up-regulation 149	
of Endophilin foci by R+S DKD primed cells to produce more FEME carriers containing β1-AR upon 150	
stimulation (Fig. 5d-f). Together, this implies a model whereby a negative feedback loop consisting of local 151	
Cdc42 inactivation by GAPs, terminates the local clustering of FBP17/CIP4, SHIP2, Lpd and Endophilin (Fig. 152	
5h). This creates short-lived membrane patches primed to bud FEME carriers that abort in absence of receptor 153	
activation.  154	
 The finding that discrete patches of the plasma membrane are primed for FEME but rapidly 155	
abort and disassemble in absence of receptor stimulation explains the promptness to form endocytic carriers 156	
upon activation. When a receptor is activated, it is recruited to pre-existing Endophilin patches that rapidly 157	
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become FEME carriers. Thus, FEME shares some similarities with CME in the generation of unproductive and 158	
abortive events in absence of receptor activation or stabilization7. However, the pre-enrichment mechanism 159	
reported here differs from Endophilin recruitment at the latest stages (just before scission) of Clathrin-coated pits 160	
or IL2Rβ-containing vesicles26. It may be that more copies of Endophilin are required during FEME than the 10 161	
to 20 molecules that recruit Dynamin at the neck of forming CME or CIE carriers26,27. The finding that active 162	
Cdc42 is required for FEME priming raises the question of potential similarities in the mechanism to that of 163	
other Cdc42-dependent CIE such as the GRAF1-mediated clathrin-independent carrier (CLIC) pathway, which 164	
is also prominent at the leading edges28-30 and relying on BAR proteins IRSp53 and PICK131. Even though 165	
Cdc42 is involved in both, it acts later during CLIC, localizing onto surface detached carriers and mediating their 166	
intracellular maturation32, instead of operating upstream during endocytic protein recruitment.  167	
The early arrival of F-BAR proteins to endocytic sites of shallow curvatures has been reported during 168	
CME where FCHo1 and 2 prime the pathway33. Mechanistically, the preceding of F-BAR proteins (FBP17 and 169	
CIP4) from N-BAR proteins (Endophilin, RICH1 and SH3BP1) is consistent with their preference for different 170	
membrane curvatures and membrane tensions27,34 and possibly aiding their temporal segregation. The presence 171	
of multiple N-BAR proteins will likely expand the cargo possibilities of the pathway. Strikingly, CIP4, Lpd, 172	
SHIP2, SH3BP1 and Endophilin are all overexpressed in various cancers35-39, suggesting a potential role for 173	
FEME in tumor formation.  174	
Finally, the potential colocalization of Endophilin with several BAR proteins other than the ones 175	
followed up in this study (Fig. 1a), opens the possibility that Endophilin could be recruited by different 176	
mechanisms, perhaps in a cell type- or cargo-specific manner to prime cells for FEME. For example, the binding 177	
of srGAP3 to Lpd40 suggests an alternative option to Endophilin recruitment to Robo axon guidance receptors or 178	
other srGAP-dependent receptors. Other BAR proteins are likely to perform additional roles than recruiting 179	
Endophilin during FEME.  180	
 181	
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Figure Legends  284	
 285	
Figure 1. FBP17 and CIP4 colocalize with Endophilin and mediate β1-AR uptake. a, Colocalization of 286	
named EGFP-tagged BAR proteins on endogenous Endophilin spots in BSC1 cells. Histograms show the mean 287	
± SEM from three independent biological experiments (n>150 puncta per construct). b, Colocalization of named 288	
endogenous BAR proteins on Endophilin spots at the leading edge of resting BSC1 cells. Histograms show the 289	
mean ± SEM from three independent biological experiments (n=150 puncta per condition). c, Intracellular 290	
accumulation of β1 adrenergic receptor (β1-AR) in Endophilin triple knocked-down (TKD), AP2 knocked-down 291	
(KD), Amphiphysin and Bin1 double knocked-down (DKD) or FBP17 and CIP4 DKD cells, treated with 10µM 292	
dobutamine for 30min. Counterstaining of the targeted proteins (red) validated the knock-downs in the cells 293	
imaged. Histograms show the mean ± SEM from three independent biological experiments (n=30 cells per 294	
condition), normalized to control cells. d, β1-AR uptake into FEME carriers (cytoplasmic Endophilin-positive 295	
assemblies) following 4min addition of 10µM dobutamine in cells depleted for FBP17 and CIP4 (F+C DKD) or 296	
not. Histograms show the mean ± SEM from three independent biological experiments (n=30 cells per 297	
condition). e, Pull-down using GST or GST-SH3 domains of Endophilin A2, FBP17, CIP4 and TOCA-1 and cell 298	
extracts expressing EGFP-tagged third intracellular loops (TIL) of β1-, β2-, β3-, α2a- or α2b-adrenergic 299	
receptors. Inputs correspond to 1 to 5% of the cell extracts. Unprocessed original scans are provided in 300	
Supplementary Fig. 6. All images are representative of at least 10 captures taken from three independent 301	
biological experiments for each condition. All experiments were repeated independently at least three times with 302	
similar results. Statistical analysis was performed by one-way ANOVA (a) or two-way ANOVA (b,c); NS, non 303	
significant P>0.99. Statistical source data are provided in Supplementary Table 2. Scale bars, 10 (c) and 5µm 304	
(b,d). 305	
 306	
Figure 2. FBP17 and CIP4 prime cells for FEME. a, colocalization of endogenous CIP4 and Endophilin in 307	
resting BSC1 cells. b, Colocalization of CIP4 on Endophilin spots at the plasma membrane but not on FEME 308	
carriers (10µM isoproterenol for 4min). c, Recruitment of endogenous CIP4 and Endophilin in resting cells 309	
depleted or not for FBP17 and CIP4 (F+C DKD) or Endophilin (Endo TKD). Histograms show the mean ± SEM 310	
from three independent biological	 experiments (n=150 cells per condition), normalized to control. d, 311	
Endogenous Endophilin cell surface spots and FEME carriers in cells overexpressing CIP4-EGFP (CIP4 OEx). 312	
Histograms show the mean ± SEM from three independent biological	experiments (n>30 cells per condition), 313	
normalized to control. e, Proximity Ligation Assays between endogenous β1-AR and Endophilin in CIP4 OEx or 314	
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control cells. Cells were pre-treated with 20nM GDC-0941 (PI3Ki) for 5min, before stimulation with 10µM 315	
dobutamine for 4min, as indicated. Histograms show the mean ± SEM from three independent biological	316	
experiments (n>30 cells per condition). f, β1-AR uptake into FEME carriers in cells overexpressing CIP4-Myc 317	
and treated as in e. Histograms show the mean ± SEM from three independent biological	 experiments (n=30 318	
cells per condition). g, Kymographs and till views from leading edge or ventral surface of resting cells 319	
expressing low levels of FBP17-EGFP and EndophilinA2-RFP and imaged at 0.5Hz (top) and 2Hz (middle). 320	
Right, percentage of maximum signals (means ± SEM, n=50 spots from three independent biological	321	
experiments). h, Kymographs from cells expressing low levels of β1-AR-EGFP or EndophilinA2-RFP and OEx 322	
or not CIP4-EGFP, treated with dobutamine and GDC-0941 as indicated and imaged at 2Hz. Kymographs are 323	
representative of 5 captures from three independent biological	experiments . Histograms show the mean ± SEM 324	
from three independent biological	experiments (n=5 cells per condition). All images are representative of at least 325	
10 captures taken from three independent biological	 experiments for each condition. All experiments were 326	
repeated independently at least three times with similar results. Statistical analysis was performed by one-way 327	
ANOVA (e,f) or two-way ANOVA (c,d,h); NS, non significant P>0.99. Statistical source data are provided in 328	
Supplementary Table 2.	Scale bars, 20 (a) and 5µm (b,c,d,f).  329	
  330	
Figure 3. FBP17 and CIP4 recruit SHIP2 and Lpd. a, Pull-down experiments with GST-tagged SH3 domains 331	
of the indicated proteins and EGFP-tagged SHIP2, Lpd or N-WASP (positive control). Inputs correspond to 1 to 332	
5% of the cell extracts. Unprocessed original scans are provided in Supplementary Fig. 6. b-e, Recruitment of 333	
endogenous CIP4, SHIP2, Lpd or Endophilin in resting BSC1 cells depleted or not for FBP17 and CIP4 (F+C 334	
DKD), SHIP (SHIP1+2 DKD) or Lpd, as indicated. Histograms show the mean ± SEM from three independent 335	
biological	experiments (n=30 cells per condition), normalized to control. f, Recruitment endogenous SHIP2 or 336	
Lpd at the leading edge of resting cells overexpressing the indicated constructs. Histograms show the mean ± 337	
SEM from three independent biological	 experiments (n=30 cells per condition), normalized to control. g, 338	
Kymograph from a cell expressing low levels of CIP4-EGFP and EndophilinA2-RFP, treated with AS19499490 339	
(SHIP2i) as indicated and imaged at 2Hz. The kymograph is representative of 9 captures from three independent 340	
biological	experiments.	 h, Proximity Ligation Assays between endogenous β1-AR and Endophilin in cells pre-341	
treated or not with 10µM AS19499490 (SHIP2i) for 5min before stimulation with 10µM dobutamine for 4min, 342	
as indicated. i,  β1-AR uptake into FEME carriers (cytoplasmic Endophilin-positive assemblies) in cells treated 343	
as in h. j,  Histograms show the mean ± SEM (left and middle, n=30 cells per condition, right, n=5 cells per 344	
condition) of cells treated as in g-i, respectively. All images are representative of at least 10 captures taken from 345	
three independent biological	experiments. All experiments were repeated independently at least three times with 346	
similar results. Statistical analysis was performed by one-way ANOVA (j, middle and right) or two-way 347	
ANOVA (e,f,j left); NS, non significant P>0.99. Statistical source data are provided in Supplementary Table 2.	348	
Scale bars, 20 (h) and 5µm (b,c,d,f,i).  349	
 350	
Figure 4. GTP-loaded Cdc42 recruits FBP17 and CIP4 to the plasma membrane. a-c, Recruitment of 351	
endogenous CIP4, SHIP2, or Endophilin in resting BSC1 cells depleted or not for Endophilin (Endo TKD), and 352	
treated with 10µM ML141 (Cdc42i 1) for 10min with as indicated. Images are representative of 10 captures 353	
from three independent biological experiments for each condition. d, Recruitment of endogenous CIP4, Lpd or 354	
Endophilin in resting cells overexpressing EGFP-tagged dominant negative (Cdc42-DN, T17N mutant) or 355	
constitutively active (Cdc42-CA, Q61L mutant) versions of Cdc42, as indicated. Focal planes were located at the 356	
bottom membrane or in the middle of the cells, as indicated. Images are representative of 6 captures from three 357	
independent biological experiments for each condition. e, Histograms show the mean ± SEM from three 358	
independent biological experiments (n=30 cells per condition), treated as in a-d and normalized to the respective 359	
controls. Secramine (Cdc42i 2) was used at 10µM for the indicated time). f, scheme of the EGFP-tagged full-360	
length or truncated versions of CIP4 used. g, h, Recruitment of EGFP-tagged full-length or truncated versions of 361	
CIP4 in cells depleted for endogenous FBP17, CIP4 and TOCA1 (TKD) and treated or not with 10µM ML141 362	
for 10min (+Cdc42i), as indicated. Cells were immunostained for endogenous CIP4 (red) to control for the 363	
depletion in the cells imaged. Images are representative of at least 6 captures taken from three independent 364	
biological experiments for each condition. Histograms show the mean ± SEM (n>6 cells per condition). All 365	
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experiments were repeated at least three times with similar results. Statistical analysis was performed by one-366	
way ANOVA (g) or two-way ANOVA (e). Statistical source data are provided in Supplementary Table 2. Scale 367	
bars, 5µm. 368	
 369	
Figure 5. Local recruitment of Cdc42GAPs terminates the priming cycle. a, Recruitment of endogenous 370	
Endophilin in resting BSC1 cells overexpressing wild-type EGFP-tagged RICH1 or R288A mutant (GAP*), as 371	
indicated. Images are representative of 10 captures from three independent biological experiments. b, 372	
Recruitment of endogenous Endophilin and RICH1 in resting cells depleted or not for Endophilin (Endo TKD) 373	
or RICH1 and SH3BP1 (R+S DKD). Images are representative of 10 captures from three independent biological 374	
experiments. c, Histograms show the mean ± SEM from three independent biological experiments (n=30 cells 375	
per condition) treated as indicated and normalized to the respective controls. d, Kymograph from a R+S DKD 376	
cell expressing low levels of CIP4-EGFP and EndophilinA2-RFP and stimulated with dobutamine at the 377	
indicated times. The kymograph is representative of 5 captures from three independent biological experiments. e, 378	
Proximity Ligation Assays between endogenous β1-AR and Endophilin in cells R+S DKD depleted pre-treated 379	
or not with 20nM GDC-0941 (PI3Ki) for 5min before stimulation with 10µM dobutamine for 4min, as indicated. 380	
f,  β1-AR uptake into FEME carriers (cytoplasmic Endophilin-positive assemblies) in cells treated as in e. g,  381	
Histograms show the mean ± SEM (left and middle, n=30 cells per condition, right, n=3 cells per condition) of 382	
cells treated as in d-f, respectively. (h) Model summarizing the priming cycle of FEME in resting cells: Step 1, 383	
active GTP-loaded Cdc42 recruits FBP17 and CIP4 through their REM domains. Step 2, FBP17 and CIP4 384	
cluster 5’-phosphatases SHIP1 and 2 as well as Lpd through their SH3 domains. Lpd is further stabilized by 385	
Pi(3,4)P2 locally produced by SHIP1/2, Step 3, Endophilin is recruited and concentrated by Lpd. From there, 386	
pre-enriched Endophilin mediates prompt FEME carrier formation upon cargo activation. In absence of cargo 387	
activation, the FEME priming complex disassembled (Step 4), upon local Cdc42 deactivation by the GAPs 388	
RICH1 and SH3BP1. All experiments were repeated at least three times with similar results. Statistical analysis 389	
was performed by one-way ANOVA (c, g middle and right) or two-way ANOVA (g left); NS, non significant 390	
P>0.99. Statistical source data are provided in Supplementary Table 2. Scale bars, 20 (e) and 5µm (a,b,f). 391	
Methods 
Cell culture. BSC1 (ECACC 85011422) and HEK293 cells (ATCC CRL-1573) were cultured in DMEM (Sigma) 
supplemented with 10% fetal bovine serum (FBS, Gold PAA), 1mM GlutaMAX-I (Gibco). Normal human epithelial cells 
hTERT-RPE1 (ATCC CRL-4000) were cultured in DMEM:F12 HAM (1:1 v/v) (Sigma), 0.25% sodium bicarbonate (w/v) 
(Sigma), 1mM GlutaMAX-I (Gibco) and 10% FBS (Gold, PAA). Approximately 2x106, 2x105, 2.5x104 or 5x103 cells were 
seeded on 100mm, 35mm dishes, 13mm coverslips or 96-well glass bottom plates, respectively. Cells were regularly tested 
for mycoplasma contamination.  
 
Gene cloning. Full length and truncated genes (all human, unless specified) were amplified and cloned into pDONR201 
(Invitrogen) and transferred into pEGFP, pTagRFP-T (called ‘RFP’ elsewhere) pMyc or pGEX-6P2 vectors converted into 
the Gateway system (pDEST vectors made from a pCI backbone), as appropriate: Arfaptin-1 (ARFIP1, IMAGE 6176474), 
Arfaptin-2 (ARFIP2, IMAGE 2821666), FAM92B (FAM92B, IMAGE8327412), ICA69 (ICA1, cloned from pMWH6 
hICA69, a kind gift from H. Kent, MRC LMB), ICA1-like (ICA1L, IMAGE 30377894), PICK1 (PICK1, IMAGE 4026028), 
Tuba (DNMBP, cloned from pcDNA3-TUBA, a kind gift of P. De Camilli, Yale U.), Tuba-L (ARHGEF37, FLJ50067), 
Amphiphysin-I (AMPHI, IMAGE 5181100), Bin1, also known as Amphiphysin-II (BIN1 iso9, cloned from human brain 
cDNA library), Bin2-EGFP has been described earlier10, Bin3 (BIN3, IMAGE 3953604), Endophilin-A1 (SH3GL2 iso1, FLJ 
92732) full length and SH3 domain (aa 295-end), Endophilin-A2 (SH3GL1, IMAGE 3458016) full length and SH3 domain 
(aa 311-end), Endophilin-A3 (SH3GL3 iso 1, IMAGE 5197246) full length and SH3 domain (aa 291-end), Endophilin B1 
(SH3GLB1, IMAGE1911531) and B2 (SH3GLB2, IMAGE3677306), RICH1, also known as Nadrin-1 (ARHGAP17, IMAGE 
6172310), RICH2, also known as Nadrin-2 (ARHGAP44, IMAGE 40125967), SH3BP1 (SH3BP1 isoform 1, 100000529), 
Oligophrenin-1 (OPHN1, cloned from human brain cDNA library), GRAF1b-EGFP (ARHGAP26 iso b, has been described 
earlier29), GRAF2 (ARHGAP10, IMAGE 40027832), APPL1 (APPL1, IMAGE 4829430), APPL2 (APPL2, IMAGE 
5168590), ACAP1, also known as Centaurin-β1 (ACAP1, cloned from pFLAG-CMV2 ACAP1, a gift from Paul Randazzo, 
NIH), ACAP2, also known as Centaurin-β2 (ACAP2, Kazusa clone KIAA0041), ACAP3, also known as Centaurin-β5 
(mouse ACAP3, cloned from pCI-FLAG ACAP3, a gift from Paul Randazzo, NIH), ASAP1 (ASAP1, IMAGE 9021132), 
ASAP2 (ASAP2, IMAGE 30345039), ASAP3 (ASAP3, a gift from Tetsuya Takeda, MRC LMB Cambridge), SNX1 (SNX1, 
IMAGE 2964409), SNX2 (SNX2, IMAGE 3048522), SNX4 (SNX4, IMAGE 4641014), SNX5 (SNX5, IMAGE 7939825), 
SNX6 (SNX6, IMAGE FLJ77179),  SNX7 (SNX7, IMAGE 4093672), SNX8 (SNX8, IMAGE 4564502), SNX9 (SNX9, 
IMAGE 3832234), SNX18 (SNX18, IMAGE 30341956), SNX30 (mouse SNX30, IMAGE 4950374), SNX32 (SNX32, 
IMAGE 4797976), SNX33 (SNX33, IMAGE 4869639), FBP17 (rat FNBP1, rapostlin-S short isoform was a kind gift from 
Manabu Negishi, Kyoto U.) full-length and SH3 domain (aa 549-end), CIP4 (TRIP10 iso2, IMAGE 3532036) full-length, F-
BAR (aa 1-264), ΔSH3 (aa 1-483), ΔF-BAR (aa 265-545), REM+SH3 (348-545), REM (aa 348-425) and SH3 (aa 483-545) 
domains, TOCA-1 (FNBP1L, a gift of J. Gallop, U. of Cambridge), Pacsin-1 (PACSIN1, IMAGE 5173129), Pacsin-2 
(PACSIN2, IMAGE 2967052), Pacsin-3 (PACSIN3, IMAGE 4302014), PSTPIP1 (PSTPIP1, IMAGE 4180398), PSTPIP2 
(PSTPIP2, IMAGE 4524856), Nostrin (NOSTRIN, IMAGE 30327154), GAS7 (GAS7, IMAGE 3353809), FCHSD1, also 
known as Nwk1 (mouse FCHSD1, IMAGE 6827858, a kind gift from H. Kent, MRC LMB Cambridge), FCHSD2, also 
known as Nwk2 (FCHSD2, FLJ56467), FCHo1-EGFP and FCHo2-EGFP have been described earlier33, FER (FER, 
FLJ96234), FES (FES, IMAGE 5170548), srGAP1 (SRGAP1, IMAGE 6526787), srGAP2 (SRGAP2, IMAGE 40146894), 
srGAP3 (SRGAP3, cloned from MEGAPa clone, a kind gift from G. Rappold, U. of Heidelberg), HMHA1 (HMHA1, 
IMAGE 5751491), ARHGAP4 (ARHGAP4, IMAGE 6379390), IRSp53 (BAIAP2, IMAGE 5562784), IRTKS (BAIAP2L1, 
IMAGE 3842949), Pinkbar (BAIAP2L2, IMAGE 4843302), MIM (MTSS1, DKFZp781P2223), ABBA-1 (MTSS1L, IMAGE 
100061592). EGFP-Lpd was described earlier41, EGFP-Cdc42, its dominant-negative (T17N) and constitutively active 
(Q61L) forms were described earlier42, EGFP-N-WASP was kind gift of Maddy Parsons (King’s College London, UK) and 
EGFP-SHIP2 was a kind gift of Frank Gertler (MIT, USA). The GAP dead mutants of RICH1 (R288A) and RICH2 (R291A) 
were kind gift of Pontus Aspenstrom (Karolinska Institute) and were subcloned into an EGFP-tagged vector. GAP dead 
mutants of SH3BP1 (R312A) and OPHN1 (R409A) and by quickchange mutagenesis and sequence verified. The sequences 
of the DNA primers used for cloning are provided in Supplementary Table 3. 
 
Gene transfection. For fixed cells colocalization experiments, cells seeded on 13mm coverslips (placed in 24-well plates) 
were transfected using Lipofectamine 2000 (Invitrogen) or Nanofectin (PAA) and 0.5 to 500ng DNA depending on the 
plasmids and the experiments (low or high overexpression). The levels of each plasmid were titrated down to low levels 
allowing good detection but limiting side effects of overexpression. Cells seeded onto live-cell imaging 35mm glass bottom 
dishes (MatTek) were transfected using Lipofectamine 2000 (Invitrogen) or Nanofectin (PAA) and 50 to 250ng DNA. For 
pull-down extracts, HEK293 cells seeded on 100mm dishes were transfected using GeneJuice (Merck) and 1 to 3µg DNA. 
Cells were incubated 24h to express the constructs and were either imaged live, fixed (4% pre-warmed paraformaldehyde, 
20min at 37°C) or processed to prepare cell extracts. 
 
siRNA suppression of gene expression. The siRNA (all Stealth, Invitrogen) used were: Endophilin A1+2+3 TKD:  Thermo 
HSS109709 (2 oligos against human SH3GL2), Thermo HSS109707 (2 oligos against SH3GL1), Thermo HSS109712 (2 
oligos against human SH3GL3); FBP17 set 1: Thermo HSS118093 (2 oligos against human FNBP1), set 2: Thermo 
HSS118094 (2 oligos against human FNBP1), set 3: Thermo HSS118095 (2 oligos against human FNBP1); CIP4 set 1: 
Thermo HSS113814 (2 oligos against human TRIP10), set 2: Thermo HSS190195 (2 oligos against human TRIP10), set 3: 
Thermo HSS113813 (2 oligos against human TRIP10); TOCA-1 set 1: Thermo HSS123422 (2 oligos against human 
FNBP1L), set 2: Thermo HSS123421 (2 oligos against human FNBP1L), set 3: Thermo HSS123423 (2 oligos against human 
FNBP1L). Double knock-down (DKD) of FBP17+CIP4 and triple knock-down (TKD) FBP17+CIP4+TOCA-1 were 
achieved by combining the oligos from the respective set 1. Lamellipodin: Dharmacon ON-TARGETplus SMARTpool (mix 
of J-031919-08, J-031919-07, J-031919-06 and J-031919-05 targeting human RAPH1) or Thermo HSS127957 (2 oligos 
against human RAPH); SHIP1: Dharmacon ON-TARGETplus SMARTpool (mix of J-003013-09, J-003013-10, J-003013-11 
and J-003013-12 targeting human INPP5D); SHIP2: Dharmacon ON-TARGETplus SMARTpool (mix of J-004152-06, J-
004152-07, J-004152-08 and J-004152-09 targeting human INPPL1); RICH1: Thermo HSS123922 (2 oligos against human 
ARHGAP17); RICH2: Thermo HSS114994 (2 oligos against human ARHGAP44); SH3BP1: Thermo HSS119062 (2 oligos 
against human SH3BP1); GRAF1: Dharmacon ON-TARGETplus SMARTpool (mix of WILDE-000564 and WILDE-000531 
targeting human ARHGAP26); GRAF2: Thermo HSS128606 (2 oligos against human ARHGAP10); OPHN1: Thermo 
HSS107440 (2 oligos against human OPHN1); AP2: HSS101955 (2 oligos against human AP2M1). Control siRNA used 
were Dharmacon ON-TARGETplus GAPDH control (D-001830-01-05), Invitrogen Stealth control (scrambled) oligo 138782 
or a mixture of Invitrogen Stealth ‘high GC’ 45-2000 and ‘low GC’ 45-2002 oligos. The sequences of the siRNA primers are 
provided in Supplementary Table 3. Cells seeded on 13 mm coverslips placed in 24 well plates were transfected twice (on 
day 1 and 2) with Oligofectamine (Invitrogen) complexed with 16 pmol of each indicated siRNA and analyzed 3-4 days after 
the first transfection. EGFP-tagged CIP4 domains targeting was performed with plasmid DNA transfection of the indicated 
constructs at the middle of day 3 (when endogenous levels of the targeted proteins were already decreased) and the cells were 
analyzed 16h later (on day 4). RNAi knock-down efficiency was verified by western-blotting and immunofluorescence 
counter-staining. The use of validated pools of siRNA targeting the same genes increased the knock-down efficiency and 
specificity.  
 
Expressed sequence tag (EST) tissue abundance. Data were recorded from the NCBI UniGene transcriptome database 
using the following entries: ARFIP1, Hs.416089; ARFIP2, Hs.75139; FAM92B, Hs.125713; ICA1, Hs.487561; ICA1L, 
Hs.516629; PICK1, Hs.180871; DNMBP, Hs.500771; ARHGEF37, Hs.256206; AMPHI, Hs.592182; BIN1, Hs.193163; 
BIN2, Hs.14770; BIN3, Hs.433722; SH3GL1, Hs.97616; SH3GL2, Hs.75149; SH3GL3, Hs.270055; SH3GLB1, Hs.136309; 
SH3GLB2, Hs.460238; ARHGAP17, Hs.373793; ARHGAP44, Hs.499758; SH3BP1, Hs.601143; OPHN1, Hs.128824; 
ARHGAP26, Hs.654668; ARHGAP10, Hs.368631; APPL1, Hs.476415; APPL2, Hs.506603; ACAP1, Hs.337242; ACAP2, 
Hs.593373; ACAP3, Hs.535257; ASAP1, Hs.655552; ASAP2, Hs.555902; ASAP3, Hs.437379; SNX1, Hs.188634; SNX2, 
Hs.713554; SNX4, Hs.507243; SNX5, Hs.316890; SNX6, Hs.356647; SNX7, Hs.197015; SNX8, Hs.584900; SNX9, 
Hs.191213; SNX18, Hs.432755; SNX30, Hs.522350; SNX32, Hs.591950; SNX33, Hs.8705; FNBP1, Hs.189409; TRIP10, 
Hs.515094; FNBP1L, Hs.515094; PACSIN1, Hs.520087; PACSIN2, Hs.162877; PACSIN3, Hs.334639; PSTPIP1, 
Hs.129758; PSTPIP2, Hs.567384; NOSTRIN, Hs.189780; GAS7, Hs.462214; FCHSD1, Hs.591257; FCHSD2, 
Hs.744959;FCHO1, Hs.96485; FCHO2, Hs.165762;FER, Hs.221472; FES, Hs.7636; SRGAP1, Hs.210751; SRGAP2, 
Hs.497575; SRGAP3, Hs.654743; HMHA1, Hs.465521; ARHGAP4, Hs.701324; BAIAP2, Hs.128316; BAIAP2L1, 
Hs.656063; BAIAP2L2, Hs.474822; MTSS1, Hs.336994; MTSS1L, Hs.432387; RAPH1, Hs.471162; SHIP1, Hs.262886; 
SHIP2, Hs.523875; GAPDH, Hs.544577. 
 
Protein purification and pull down experiments. GST-tagged SH3 domains were expressed in BL21-codonPlus(DE3)-RP 
E.coli (Stratagene).  Cells were lysed using either by sonication or using Emulsiflex C3, spun at 18,000 to 140,000g for 20 to 
40min (depending on the construct) at 4°C and the supernatants were bound to glutathione beads for 30min to 1h. The beads 
were washed extensively with 150mM NaCl, 20mM HEPES pH 7.4, 2mM DTT, 2mM EDTA, including 2 washes with 
500mM NaCl or five times with ice cold PBS. GST-proteins were eluted from the GST-sepharose beads with 10mM 
glutathione, further purified by Superdex 200 gel filtration, and rebound to a minimal volume of fresh GST-sepharose beads 
(to achieve saturation) for use in pull downs. Brain lysates (5-10mg/mL) were prepared in lysis buffer (150mM NaCl, 20mM 
HEPES, 5mM DTT, 0.1% Triton X-100 and a protease and phosphatase inhibitor cocktail (Thermo Scientific)). Bead-bound 
proteins were then exposed to rat brain or cell lysates for 30min to 1h on ice, pelleted in a cooled desktop centrifuge, and 
washed three times in lysis buffer. The final pellet was boiled in sample buffer and ran on SDS-PAGE. For protein 
identification, Coomassie Brilliant Blue-stained protein bands were excised from the gels and underwent LC-MS-MS mass 
spectrometry (Thermo Orbitrap) for identification. For candidate validation, HEK293 cells expressing various EGFP-tagged 
constructs were quickly washed with cold PBS, lysed in ice-cold lysis buffer (as above or 50mM Tris HCL, 200mM NaCl, 
1% NP-40, 2mM MgCl2, 10% glycerol, pH 7.4, 1mM Na3VO4, 10mM NaF, and protease inhibitors ‘Complete mini without 
EDTA’,  Roche), briefly sonicated and spun at 14,000 to 17,000g for 10 to 15min at 4°C. Protein concentration was then 
determined (Pierce BCA protein assay kit; Thermo Fisher Scientific). Bead bound proteins were then incubated with cell 
lysates for 1 to 2h, pelleted in a cooled benchtop centrifuge, and washed three times in lysis buffer. The final pellets were 
boiled in sample buffer and ran on SDS-PAGE (‘input’ lanes correspond to 1 to 10% of cell extracts). The proteins were 
transferred onto PVDF membrane and immunoblotted using anti-EGFP antibodies, followed by HRP-coupled secondary 
antibodies (BioRad or Dako). Blots were developed with the ECL kit (Thermo Fischer Scientific or Merck Millipore) and x-
ray film, or the Immun-Star WesternC ECL kit (Bio-Rad Laboratories) using the Bio-Rad Imager and ImageLab software.  
 
Co-immunoprecipitations. RPE1 or HEK293 cells were co-transfected with equal amounts of Myc- and EGFP-tagged BAR 
domain constructs. After 16-24h expression,  cells were quickly washed with cold PBS, lysed in ice-cold lysis buffer (10mM 
Tris HCL pH7.5, 150mM NaCl, 0.5mM EDTA, 0.5% NP40 and a protease and phosphatase inhibitor cocktail (Thermo 
Scientific)) and spun at 14,000g for 10min at 4°C. Cell lysates were incubated with GFP-TRAP_A (Chromotek) bead slurry 
for up to 16h at 4°C. The beads were washed 3 times (10mM Tris HCL pH7.5, 150mM NaCl, 0.5mM EDTA).  The final 
pellets and unbound fractions were boiled in sample buffer and ran on SDS-PAGE (‘input’ lanes correspond to 1 to 10% of 
cell extracts). The proteins were transferred onto PVDF membrane and immunoblotted using anti-Myc or anti-EGFP 
antibodies, followed by HRP-coupled secondary antibodies (BioRad). Blots were developed with the ECL kit (Thermo 
Fischer Scientific or Merck Millipore) and x-ray films.  
 
Chemicals and small inhibitors. Dobutamine (β1 adrenergic receptor partial agonist, Sigma, D0676) was used at 10µM, 
Alexa Fluor 488-Transferrin (Life Technologies T13342) was used at 20µg/mL, GDC-0941 (called ‘PI3Ki’ in this study, 
Symansis SYG0941) was used at 5 to 20nM; AS19499490 (called ‘SHIP2i’ in this study, Tocris 3718) was used at 0.5 to 
10µM; ML141 (Cdc42 allosteric inhibitor, called ‘CDC42i 1’ in this study, Tocris 4266) was used at 10µM and secramine 
(Cdc42 inhibitor, called ‘CDC42i 2’ in this study, was a kind gift from T. Kirchhausen (Harvard Medical School) and the 
Hammond lab (U. of Louisville) and was synthetized by Bo Xu and GB Hammond and was used at 10µM. 
 
Cell stimulation and cargo uptake. Cells were never serum-starved or pre-incubated at 4°C. ‘Resting’ conditions 
correspond to cells being cultured in 10% serum media and directly fixed. β1 adrenergic receptor stimulation (which 
activates FEME) was performed by incubating cells at 37°C for 30sec to 30min with pre-warmed medium containing 10µM 
dobutamine. EGF stimulation was performed by incubating cells at 37°C for 30sec with pre-warmed medium containing 
50ng/mL EGF. In some experiments, cells were incubated with pre-warmed medium containing 50µg/mL Alexa Fluor-488 
labeled human transferrin (CME cargo) and 10µM dobutamine at 37°C for 30 seconds. After the incubation periods at 37°C, 
cells stimulated as described above were quickly washed once with 37°C pre-warmed PBS to removed unbound ligands and 
fixed with pre-warmed 4% PFA for 20min at 37°C. Fixed cells were then washed three times with PBS and one time with 
PBS supplemented with 50mM NH4Cl to quench free PFA. Cells were then permeabilized (0.05% saponin), immunostained 
and imaged as described below. 
 
Antibodies. The following antibodies were used for immunostaining or immunoblotting: anti-Endophilin A2 clones H-60 
and A-11 (rabbit polyclonal sc-25495 and mouse monoclonal sc-365704, respectively, Santa Cruz Biotechnology), anti-β1 
adrenergic receptor (rabbit polyclonal, AbCam ab3442 for immunostaining or Thermo Scientific PA1-049 for western-
blotting), anti-Lamellipodin (Lpd) (mouse monoclonal clone H-5, Santa Cruz sc-390050 and rabbit polyclonal, Atlas 
Antibodies HPA020027), anti-CIP4, (mouse monoclonal clone 21, Santa Cruz sc-135868), anti-Bin1 (rabbit polyclonal, 
GeneTex GTX103259), anti-RICH1 (rabbit polyclonal, Bethyl Labs A304-689A), anti-SNX9 (mouse monoclonal clone 2F1, 
AbCam ab118996), anti-Pacsin2 (rabbit polyclonal, Abgent AP8088b), anti-srGAP1 (mouse monoclonal clone 5D2, Abnova 
H00057522-M03), anti-ASAP1 (mouse monoclonal clone P7Q, Santa Cruz sc-81896), anti-SHIP2 (mouse monoclonal clone 
3E6, Novus Biological H00003636-M01 or rabbit monoclonal clone C76A7, Cell Signaling Technologies 2839), anti-α-
adaptin clone 8 (mouse monoclonal, BD Bioscience 610501), anti-GAPDH clone 14C10 (rabbit polyclonal, Cell Signaling 
Technologies 2118), anti-LAMP-1 (mouse monoclonal clone H4A3-c, Developmental Studies Hybridoma Bank or rabbit 
polyclonal D2D11, Cell Signaling Technologies 9091), anti-EGFP (rabbit polyclonal, AbCam ab290 or mouse monoclonal 
clones 7.1 and 13.1, Roche 11814460001), anti-Myc tag clone 71D10 (rabbit monoclonal, Cell Signaling Technologies 
2278). Primary antibodies were used at 0.1 to 1µg/mL for immunoblotting and 0.1 to 2µg/mL for immunofluorescence. The 
following secondary antibodies were used: AlexaFluor 488 (A-11001) and AlexaFluor 555 (A-21422) Goat anti-Mouse IgG, 
AlexaFluor 488 (A-11008) and AlexaFluor 555 (A-21428) Goat anti-Rabbit IgG (all from Thermo Scientific) and Goat anti-
Mouse IgG-HRP conjugate (1706516) and Goat anti-Rabbit IgG-HRP conjugate (1706516) from Bio-Rad. See 
Supplementary Table 4 for full antibody details. 
 
Immunostaining, proximity ligation assays, laser scanning confocal fluorescent microscopy and analysis. Fixed 
samples were permeabilized (0.05% saponin) and immunostained (primary and secondary antibodies were diluted in 5% 
BSA). In some experiments, Phalloidin-AlexaFluor 647 (Cell Signaling Technologies 8940) was added with secondary 
antibodies. Proximity ligation assays (PLA) were performed using Duolink PLA technology (kit DUO92101, Sigma), 
following instructions given by the manufacturer. The coverslips were mounted with DABCO anti-fade agent on glass slides 
and imaged using a laser scanning confocal microscope (TCS Sp5 AOBS; Leica) equipped with a 63x objective. For 
Alexa488, the illumination was at 488nm and emission collected between 498 and 548nm; for Alexa555 the laser 
illumination was at 543nm and emission collected between 555 and 620nm; for Alexa647 and DRAQ5, the laser illumination 
was at 633nm and emission collected between 660 and 746nm. The percentages of colocalization of BAR proteins with 
Endophilin spots located at the leading edge of cells were determined using Volocity 6.0. The levels of CIP4 EGFP-tagged 
constructs at the leading edges of cells were measured on masks covering a total at least 100µm long (~2µm wide) of leading 
edge of at least 3 cells from 3 independent experiments using Volocity 6.0.  
 
Live-cell confocal fluorescent microscopy.  Just before live-cell imaging, the medium of cells grown on MatTek dishes was 
changed to α-MEM without phenol red, supplemented with 20mM HEPES, pH 7.4 and 5% FBS and placed into a 
temperature controlled chamber on the microscope stage with 95% air: 5% CO2 and 100% humidity. Live-cell imaging data 
were acquired using a fully motorized inverted microscope (Eclipse TE-2000, Nikon) equipped with a CSU-X1 spinning disk 
confocal head (UltraVIEW VoX, Perkin-Elmer, England) using a 60x lens (Plan Apochromat VC, 1.4 NA, Nikon) under 
control of Volocity 6.0 (Improvision, England). 14-bit digital images were obtained with a cooled EMCCD camera (9100-02, 
Hamamatsu, Japan). Four 50mW solid-state lasers (405, 488, 561 and 647nm; Crystal Laser and Melles Griots) coupled to 
individual acoustic-optical tunable filter (AOTF) were used as light source to excite EGFP, Alexa488, TagRFP-T, Alexa555 
and 647, as appropriate. Rapid two-colour time-lapses were acquired at 500ms to 2s intervals, using a dual (525/50; 640/120, 
Chroma) emission filter respectively. The power of the lasers supported excitation times of 50 ms in each wavelength and the 
AOTFs allowed minimum delay (~1ms) between 2 colors (e.g. delay between green-red for each timepoint), which was an 
important factor to assess the colocalization between markers. 
 
Plasma membrane isolation. Cell surface protein isolation, excluding intracellular proteins, was performed as in4, by 
selective biotinylation using a cell-impermeable cleavable biotinylation reagent (Sulfo-NHS-SS-Biotin), followed by 
purification of surface proteins by affinity-purified NeutrAvidin agarose resin (Thermo Scientific 89881). 
 
Statistics and reproducibility. The samples sizes and statistical tests were selected based on previous studies with similar 
methodologies. Sample sizes were not determined using statistical methods. All experiments were independently repeated at 
least three times, giving similar results. For all figures, results shown are mean ± standard error of the mean (SEM). 
Statistical testing was performed using Prism 6 (GraphPad Software). Comparisons of data in Fig. 1a, 2e, 2f, 3j middle, 3j 
right, 4g, 5c and 5g middle were performed by one-way analysis of variance (ANOVA) with Tukey’s multiple comparison 
test. Comparisons of all other data were performed by two way ANOVA with Tukey’s multiple comparisons test. P values 
<0.01 were considered significant.  
 
Reporting Summary. Further information on experimental design is available in the Reporting Summary. 
 
Data availability. The source data for statistical analysis of Figs. 1a-c, 2c, 2d-f, 2h, 3e-f, 3j, 4e, 4g, 5c and 5g are provided in 
Supplementary Table 2. The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium 
via the PRIDE43 partner repository with the dataset identifier PXD010090 and DOI 10.6019/PXD010090. Uncropped gels 
and blots are provided in Supplementary Fig. 6. All other data that support the findings of this study are available from the 
corresponding author upon reasonable request.  
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Figure 1. CIP4 and FBP17 colocalize with Endophilin in resting cells and mediate β1-AR uptake upon stimulation
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Figure 2. CIP4 and FBP17 prime cells for FEME
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Figure 3. CIP4 and FBP17 recruit SHIP2 and Lpd to prime FEME
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Figure 4. GTP-loaded Cdc42 recruits CIP4 at the plasma membrane
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Figure 5. Local recruitment of Cdc42GAPs terminates the priming cycle
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Supplementary Figure 1 
BAR domain proteins binding to Endophilin 
a, Pull down using GST-SH3 domains for Endophilin A1, A2 or A3 and rat brain lysate. Interacting proteins were identified by mass spectrometry. Known 
interactors are shown in grey, members of the WAVE complex in black and BAR-domain proteins in blue. Asterisk denotes GST-SH3. List of identified 
proteins is provided in Supplementary Table 1. b, Pull-down using GST-SH3 domains of Endophilin A2 and cell extracts expressing EGFP-tagged 
indicated BAR proteins. Bin2 and OPHN1 were used as positive controls. GST was used as negative control. Binding proteins were detected by 
immunoblotting with an anti-EGFP antibody.  ‘input’ lanes correspond to 1-5 % of the cell extracts. c, Schematic depicting the domain organization of the 
human full-length BAR domain-containing proteins cloned and used in this study. d, co-immunoprecipitation assays from cells co-expressing the 
indicated combination of EGFP- or Myc-tagged BAR domains from FBP17, CIP4 and TOCA-1 and showing that all three can heterodimerize. Input (‘I’, 
which corresponds to 10% of cell extracts), unbound (‘U’) and bound (‘B’) fractions for each were immunoblotted with anti-EGFP and anti-Myc 
antibodies. All experiments were repeated independently at least three times with similar results. Unprocessed original scans are provided in 
Supplementary Fig. 6. 
 
 
 
Supplementary Figure 2 
BAR domain-containing proteins tissue expression pattern. 
a, Number of tissues where expressed sequence tag (EST) were detected in the UniGene transcriptome database for the named human BAR domain-
containing proteins. Zones for expression in 25% and 50% of the tissues are highlighted in dark and light red, respectively. b, Number of transcript per 
million (TPM) in kidney (tissue of origin of BSC1 cells) for the named human BAR domain-containing proteins recorded in the UniGene transcriptome 
database. Red boxes highlights genes for which no transcript were detected. c, Number of transcript per million (TPM) in eye (tissue of origin of RPE1 
cells) for the named human BAR domain-containing proteins recorded in the UniGene transcriptome database. Red boxes highlights genes for which no 
transcript were detected. The data were recorded from the NCBI UniGene transcriptome database (see Methods for details) [AU please mention how 
many times the experiment was performed if once please state this.]  
 
 
 
 
Supplementary Figure 3 
BAR proteins colocalizing with Endophilin in resting cells. 
a, Confocal microscopy sections showing an example of the named BAR proteins tagged with EGFP at their C-termini  colocalizing (RICH1-EGFP, left) 
or not (RICH2-EGFP, right) with endogenous Endophilin in BSC1 cells. b, Criteria used to score BAR candidates negative or positive. Intensity profiles 
were acquired along the indicated lines. c-f, Confocal microscopy sections showing the colocalization of the named controls (soluble EGFP and CAAX-
EGFP), BAR, N-BAR or BAR-PH proteins tagged with EGFP at their C-termini and Endophilin. Images were cropped from larger pictures and angled as 
in (a) so that all images are oriented similarly. Arrowheads point to Endophilin spots colocalizing with BAR proteins at the cell surface. Images are 
representative of 10 captures from three independent biological experiments. All experiments were repeated independently at least three times with 
similar results. Scale bars, 5 µm. 
 
 
 
Supplementary Figure 4 
BAR proteins colocalizing with Endophilin in resting cells (continued). 
a-c, Confocal microscopy sections showing the colocalization of the named PX-BAR, F-BAR or I-BAR proteins tagged with EGFP at their C-termini and 
Endophilin in BSC1 cells. Arrowheads point to Endophilin spots colocalizing with BAR proteins at the cell surface. Images are representative of 10 
captures from three independent biological experiments. d, Absence of colocalization between internalized Alexa488-Transferrin and endogenous 
Endophilin in BSC1 and RPE1 cells stimulated with 10µM dobutamine and 50µg/mL Alexa488-Transferrin for 30sec at 37°C for 30sec. Images are 
representative of 10 captures from three independent biological experiments. e, Top, β1-AR and GAPDH levels in the indicated plasma membrane and 
total fractions from BSC1 cells depleted or not for Endophilin (Endo TKD), AP2, FBP17 and CIP4 (F+C DKD) or Amphiphysin and Bin1 (A+B DKD). 
 
 
Unprocessed original scans are provided in Supplementary Fig. 6. f, Colocalization of β1-adrenergic receptor (β1-AR) and LAMP1 in resting BSC1 cells 
or upon incubation with 10µM dobutamine for 30min. Images are representative of 6 captures from three independent biological experiments. All 
experiments were repeated independently at least three times with similar results. Scale bars, 20 (f) and 5µm (a,,b,c,d). 
 
 
 
 
Supplementary Figure 5 
Cdc42 is deactivated locally by RICH1 and SH3BP1. 
a, Confocal microscopy sections showing the transient increase in endogenous CIP4 and Endophilin on FEME carriers after 2 but not 10min incubation 
with 10µM ML141 (‘Cdc42i 1’). Images are representative of 6 captures from three independent biological experiments. b, Confocal microscopy section 
showing the decrease or not in endogenous Endophilin recruitment at the leading edge of resting cells overexpressing wild-type EGFP-tagged RICH2, 
SH3BP1 or OPHN1 but not their R291A, R312A and R409A respective GAP mutants (GAP*). Arrowheads point to Endophilin spots at the cell surface. 
Images are representative of 6 captures from three independent biological experiments. c,d, Recruitment of endogenous RICH1, Lpd and CIP4 in 
resting BSC1 cells depleted or not for Lamellipodin (Lpd KD) , RICH1 and SH3BP1 (R+S DKD) or FBP17 and CIP4 (F+C DKD). Images are 
representative of 10 captures from three independent biological experiments. e, Pull-down using GST or GST-SH3 domains of Endophilin A2 or FBP17 
and cell extracts expressing RICH1, RICH2, SH3BP1 or OPHN1 tagged with EGFP at their C-termini. Inputs correspond to 1 to 5% of the cell extracts. 
All experiments were repeated independently at least three times with similar results. Unprocessed original scans are provided in Supplementary Fig. 6. 
Bars, 5 µm. 
 
 
 
 
Supplementary Figure 6 
Unprocessed original scans of all gels and blots. 
 
 
 
 
Supplementary Figure 6 
 Unprocessed original scans of all gels and blots (continued). 
 
 
 
 
Supplementary Figure 6 
Unprocessed original scans of all gels and blots (continued). 
 
 
 		
Supplementary Table legends 
 
Supplementary Table 1 List of interactors identified in Supplementary Fig. 1a. Number of unique peptides and percentage of protein 
coverage is indicated.   
 
Supplementary Table 2 Statistics Source Data. The source data for statistical analysis of Figure 1a-c, 2c-f, 2h, 3e-f, 3j, 4e, 4g, 5c and 
5g. 
 
Supplementary Table 3 Sequences of DNA and siRNA primers used in this study. 
 
Supplementary Table 4 Information on antibodies used in this study. 
 
 
Supplementary Video legends 
 
Supplementary Video 1 Spinning-disk confocal microscopy of a resting BSC1 cell transiently expressing low levels of EGFP-LCa 
(clathrin, green) and Endophilin A2-RFP (red) and imaged at 0.5 Hz. The cell was imaged at 37°C in normal imaging medium (5% 
serum but in absence of cargo stimulation). Note the numerous Endophilin puncta flashing on the leading edge but not budding into the 
cytoplasm. The experiment was repeated at least three times with similar results. The video is playing at 10 frames/sec.  
 
Supplementary Video 2 Spinning-disk confocal microscopy of a resting BSC1 cell transiently expressing low levels of FBP17-EGFP 
(green) and Endophilin A2-RFP (red) and imaged at 0.5 Hz. The cell was imaged at 37°C in normal imaging medium (5% serum but in 
absence of cargo stimulation). Note the numerous FBP17 and Endophilin puncta flashing all along the leading edge but not budding 
into the cytoplasm. The experiment was repeated at least three times with similar results. The video is playing at 10 frames/sec. 
 
Supplementary Video 3 Spinning-disk confocal microscopy of a resting BSC1 cell transiently expressing low levels of CIP4-EGFP 
(green) and Endophilin A2-RFP (red) and imaged at 2 Hz. The cell was imaged at 37°C in normal imaging medium (5% serum but in 
absence of cargo stimulation). 5 nM GDC-0941 (PI3Ki) was added at timeframe 100. Note that inhibiting PI3K blocked CIP4 and 
Endophilin recruitment. The experiment was repeated at least three times with similar results. The video is playing at 1 frame/sec. 
 
Supplementary Video 4 Spinning-disk confocal microscopy of a resting BSC1 cell transiently expressing low levels of FBP17-EGFP 
(green) and Endophilin A2-RFP (red) and imaged at 2 Hz. The cell was imaged at 37°C in normal imaging medium (5% serum but in 
absence of cargo stimulation). Note the numerous FBP17 flashes preceding Endophilin puncta. The experiment was repeated at least 
three times with similar results. The video is playing at 10 frames/sec. 
 
Supplementary Video 5 Spinning-disk confocal microscopy of a resting BSC1 cell transiently expressing low levels of CIP4-EGFP 
(green) and Endophilin A2-RFP (red) and imaged at 2 Hz. The cell was imaged at 37°C in normal imaging medium (5% serum but in 
absence of cargo stimulation). Note the numerous CIP4 flashes preceding Endophilin puncta. The experiment was repeated at least 
three times with similar results. The video is playing at 10 frames/sec. 
 
Supplementary Video 6 Spinning-disk confocal microscopy of a resting BSC1 cell transiently expressing low levels of CIP4-EGFP 
(green) and Endophilin A2-RFP (red) and imaged at 2 Hz. The cell was imaged at 37°C in normal imaging medium (5% serum but in 
absence of cargo stimulation). 5 µM AS19499490 (‘SHIP2i’) was added at timeframe 100 and again at timeframe 200. Note that 
inhibiting SHIP2 slowed CIP4 and Endophilin recruitment. The experiment was repeated at least three times with similar results. The 
video is playing at 10 frame/sec. 
 
